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Abstract
Objectives: Nonalcoholic fatty liver disease (NAFLD) is associated with advanced atherosclerosis and a higher risk of
cardiovascular disease. Increasing evidence suggests that injured endothelial monolayer is regenerated by circulating bone
marrow derived-endothelial progenitor cells (EPCs), and levels of circulating EPCs reflect vascular repair capacity. However,
the relation between NAFLD and EPC remains unclear. Here, we tested the hypothesis that patients with nonalcoholic fatty
liver disease (NAFLD) might have decreased endothelial progenitor cell (EPC) levels and attenuated EPC function.
Methods and Results: A total of 312 consecutive patients undergoing elective coronary angiography because of suspected
coronary artery disease were screened and received examinations of abdominal ultrasonography between July 2009 and
November 2010. Finally, 34 patients with an ultrasonographic diagnosis of NAFLD, and 68 age- and sex-matched controls
without NAFLD were enrolled. Flow cytometry with quantification of EPC markers (defined as CD34
+, CD34
+KDR
+, and
CD34
+KDR
+CD133
+) in peripheral blood samples was used to assess circulating EPC numbers. The adhesive function, and
migration, and tube formation capacities of EPCs were also determined in NAFLD patients and controls. Patients with
NAFLD had a significantly higher incidence of metabolic syndrome, previous myocardial infarction, hyperuricemia, and
higher waist circumference, body mass index, fasting glucose and triglyceride levels. In addition, patients with NAFLD had
significantly decreased circulating EPC levels (all P,0.05), attenuated EPC functions, and enhanced systemic inflammation
compared to controls. Multivariate logistic regression analysis showed that circulating EPC level (CD34
+KDR
+ [cells/10
5
events]) was an independent reverse predictor of NAFLD (Odds ratio: 0.78; 95% confidence interval: 0.69–0.89, P,0.001).
Conclusions: NAFLD patients have decreased circulating EPC numbers and functions than those without NAFLD, which may
be one of the mechanisms to explain atherosclerotic disease progression and enhanced cardiovascular risk in patients with
NAFLD.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent
condition characterized by fatty infiltration of liver cells. The
clinical manifestations of NAFLD resemble those of alcohol-
induced liver injury, but NAFLD occurs in patients who do not
abuse alcohol [1]. The prevalence of NAFLD is generally between
10% and 40% in various populations, and it is also the most
common cause of abnormal results in liver function tests [2–4].
There is growing evidence that NAFLD, a hepatic manifestation
of the metabolic syndrome [5], is strongly associated with obesity,
insulin resistance, enhanced systemic inflammation, and advanced
atherosclerosis, independent of shared cardiometabolic risk factors
[6,7]. Previous studies have suggested that non-obese subjects with
NAFLD have a significantly increased cardiovascular disease risk
[8,9]. However, the pathophysiologic mechanisms underlying the
evolution from NAFLD to atherosclerosis and cardiovascular
events remain to be determined.
Convincing evidence indicates that atherosclerosis is associated
with endothelial dysfunction at the early stage of the disease
process [10]. Intact endothelium and maintenance of endothelial
integrity play a pivotal role in preventing the development of
atherosclerotic vascular disease [11]. Recent insight suggests that
the injured endothelial monolayer is regenerated by circulating
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31799bone marrow derived-endothelial progenitor cells (EPCs) [12], and
levels of circulating EPCs reflect endothelial repair capacity [13].
An altered status of circulating EPCs represents a marker of
endothelial dysfunction and vascular health, and the level of
circulating EPCs could be used as a surrogate index of cumulative
cardiovascular risk [14]. Circulating EPC number has also been
reported to inversely correlate with presence of risk factors of
coronary artery disease [14–16]. Furthermore, a reduced number
of circulating EPCs independently predicts atherosclerotic disease
progression and future cardiovascular events [17]. Clinical studies
have indicated that NAFLD is associated with arterial stiffness and
endothelial dysfunction [18,19]. However, no previous report has
mentioned the role of circulating EPCs in patients with NAFLD.
In this study, we tested the hypothesis that decreased circulating
EPC levels and function might be associated with NAFLD and
that this could be one mechanism to explain the higher risk of
cardiovascular disease among NAFLD patients.
Methods
Study participants
We initially screened a total of 312 consecutive patients, who
were admitted to Taipei Veterans General Hospital between July
2009 and November 2010 to undergo elective coronary
angiography because of suspected coronary artery disease.
Subjects were excluded from the study on the basis of the
following criteria: (1) presence of serological markers of hepatitis B
virus (hepatitis B surface antigem and anti-HBs antibody) and
hepatitis C virus infection (anti-HCV antibody); (2) presence of
autoimmune liver disease or alcoholic liver disease (alcohol intake
more than 20 g per day by using a questionnaire); (3) presence of
malignant diseases, or (4) clinical evidence of unstable angina,
myocardial infarction, congestive heart failure, valvular heart
disease, inflammatory disease, or thyroid dysfunction. The
presence of NAFLD was identified by ultrasonographic findings.
Abdominal ultrasonography was performed before examination of
the coronary angiography by two of four experienced gastroen-
terologists, who were blinded to the clinical presentation and
laboratory findings. The severity of fatty liver was graded as
follows: (1) mild, defined as a slight, diffuse increase in liver
echogenicity in the hepatic parenchyma with normal visualization
of the diaphragm and the portal veins; (2) moderate, defined as a
moderate, diffuse increase in liver echogenicity with slightly
impaired visualization of the diaphragm and the portal veins; (3)
severe, defined as a marked increase in liver echogenicity with
poor or no visualization of the diaphragm and the portal veins
[20]. To decrease inter-observer variation, the ultrasonographic
severity of NAFLD measured by individual gastroenterologist was
randomly monitored and reviewed by a senior gastroenterologist.
In case of disagreement, the opinion of the third observer was
obtained, and the final decision was made by consensus.
On the basis of these screening criteria, 34 patients with a
diagnosis of NAFLD, as the study group, and 68 age- and gender-
matched patients without NAFLD, as controls, were enrolled in
this study. Medical history, including information about conven-
tional cardiovascular risk factors (smoking, hypertension, diabetes
mellitus, hyperlipidemia, peripheral artery disease, and chronic
kidney disease), previous cardiovascular events (myocardial
infarction and cerebrovascular disease), and current drug
treatment was obtained during a personal interview and from
medical files. Coronary artery disease was defined as having §
50% stenosis of one or more of the major coronary arteries on the
basis of the results of coronary angiography. Diagnosis of
metabolic syndrome was based on the definition proposed by
the National Cholesterol Education Program Adult Treatment
Panel III (NCEP ATP III). The waist circumference cut-off point
in the ATP III criteria was revised as suggested by the 2000 World
Health Organization (WHO) Asia-Pacific Guidelines, because the
absolute risk of diabetes and cardiovascular disease is higher in
Asians, who are less obese [21]. Presence of any 3 of following
criteria was considered grounds for diagnosis of metabolic
syndrome: (1) fasting glucose $100 mg/dL or treated for diabetes;
(2) waist circumference .90 cm in men and .80 cm in women;
(3) blood pressure $130/$85 mmHg or pharmacological treat-
ment for high blood pressure; (4) triglyceride levels $150 mg/dL
or current use of fibrates, and (5) high-density lipoprotein
cholesterol (HDL-C) ,40 mg/dL in men and ,50 mg/dL in
women.
Ethics statements
This study was approved by Taipei Veterans General Hospital
research ethics committee. All patients gave written informed
consent and research was conducted according to the principles
expressed in the Declaration of Helsinki.
Laboratory investigations
Blood pressure was recorded as the average of 3 different
measurements taken after 15-minute resting periods. Body mass
index (BMI) was calculated by dividing the weight of the patient in
kilograms by the square of the height in meters. Waist
circumference was measured in a standard position at the level
of the umbilicus. Venous blood was drawn in the morning after an
overnight fast. Plasma liver function tests and other biochemical
blood measurements, including assessments of fasting blood
glucose, uric acid, creatinine, total cholesterol, high-density
lipoprotein cholesterol (HDL-C), gamma-glutamyl transferase
(cGT), and triglyceride levels were performed by standard
laboratory procedures. All participants had negative results in
serological tests for hepatitis B or C. High sensitivity C-reactive
protein (hsCRP) levels in plasma were assessed using the latex-
enhanced immunonephelometric assay (Dade Behring, Marburg,
Germany) [22]. Plasma asymmetric dimethylarginine (ADMA)
levels were determined using a quantitative sandwich enzyme
immunoassay technique with an ADMA enzyme-linked immuno-
sorbent assay kit (DLD Diagnostika GmbH, Hamburg, Germany)
[23]. The intra-assay and inter-assay variation coefficients were
not more than 4% and 8%, respectively [24].
Assay of circulating EPCs
Assessment of the circulating EPCs by flow cytometry was
performed by the researchers masked to the clinical data [25]. A
volume of 1000-mL peripheral blood was incubated for 30 minutes
in the dark with monoclonal antibodies against human KDR
(R&D, Minneapolis, MN, USA) followed by Allophycocyani-
n(APC)-conjugated secondary antibody, with the fluorescein
isothiocyanate (FITC)-labeled monoclonal antibodies against
human CD45 (Becton Dickinson, Franklin Lakes, NJ, USA), with
the PE-conjugated monoclonal antibody against human CD133
(Miltenyi Biotec, Germany), and with FITC-conjugated monoclo-
nal antibodies against human CD34 (Becton Dickinson Pharmin-
gen, USA). After incubation, cells were lysed, washed with
phosphate-buffered saline (PBS), and fixed in 2% paraformalde-
hyde before analysis. Each analysis included 150,000 events. As
shown in Figure 1, the numbers of circulating EPCs were gated
with monocytes and defined as CD34
+CD45
low,
CD34
+KDR
+CD45
low, and CD34
+KDR
+CD133
+CD45
low, re-
spectively. The number of CD34
+, CD34
+KDR
+, and
CD34
+KDR
+CD133
+ cells was normalized and expressed per-
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5 events. To assess the
reproducibility of EPC measurements, circulating EPCs were
measured from 2 separate blood samples in 10 subjects, and there
was a strong correlation between the two measurements (r=0.90,
P,0.001).
Human early and late EPC cultivation
Peripheral blood samples (20 ml) were obtained from study
populations, and total mononuclear cells (MNCs) were isolated by
density gradient centrifugation with Histopaque-1077 (Sigma, St.
Louis, MO, USA) [23]. Briefly, MNCs (5610
6) were plated in
2 ml endothelial growth medium (EGM-2 MV Cambrex, East
Rutherford, NJ, USA) on fibronectin-coated 6-well plates. After 4
days of culturing, the medium was changed and nonadherent cells
were removed; attached early EPCs appeared elongated with a
spindle shape. A certain number of MNCs were allowed to grow
into colonies of late EPCs, which emerged 2–4 weeks after the start
of the MNC culture. The late EPCs exhibited a ‘‘cobblestone’’
morphology and monolayer growth pattern typical of mature
endothelial cells at confluence. Both early and late EPCs were
collected and used for the functional assays in this study. The
characteristics and phenotype of the early and late EPC were
defined by flow cytometry (Figure S1).
EPC characterization
The early EPCs were characterized as adherent cells double
positive for acetylated low-density lipoprotein uptake and lectin
binding by direct fluorescent staining as previously described [26].
The early and late EPCs were characterized by immunofluores-
cence staining for the expression of VE-cadherin, platelet/
endothelial cell adhesion molecule-1 (PECAM-1) (CD-31),
CD34, KDR (VEGFR-2), and AC133 (Santa Cruz Biotechnology,
Inc., CA, USA). The fluorescent images were recorded under a
laser scanning confocal microscope.
Fibronectin adhesion assay of EPCs
Early EPCs (day 7) from 16 subjects (8 NAFLD patients and 8
controls) were washed with phosphate-buffered saline and gently
detached with 0.5 mmol/L EDTA in phosphate-buffered saline.
The basic characteristics of those 2 groups were similar (Table S1).
After centrifugation and re-suspension in basal medium with 5%
fetal bovine serum, identical cells were placed on a fibronectin-
coated 6-well plate and incubated for 30 min at 37uC. Gentle
washing with phosphate-buffered saline was performed 3 times
after adhesion for 30 minutes, and adherent cells were counted by
independent blinded investigators [26]. Phenotyping of the
endothelial characteristics of adherent cells by indirect immuno-
staining was performed with FITC-labeled lectin from Ulex
europaeus (UEA-1). Briefly, the adherent cells were fixed in 2%
paraformaldehyde and incubated with 10 mg/mL FITC-labeled
UEA-1 (Sigma) as previously described [26].
EPC migration test
The migratory function of late EPCs was evaluated by a
modified Boyden chamber assay (Transwell, Coster, San Diego,
CA, USA) [23]. Briefly, isolated EPCs were detached as described
above with trypsin/EDTA and then 4610
4 late EPCs were placed
in the upper chambers of 24-well Transwell plates with
polycarbonate membrane (8-mm pores) with serum-free endothe-
lial growth medium; VEGF (50 ng/ml) in medium was placed in
the lower chamber. After incubation for 24 hours, the membrane
was washed briefly with PBS and fixed with 4% paraformalde-
hyde. The membrane was then stained using hematoxylin solution
and carefully removed. The magnitude of migration of the late
Figure 1. Representative flow cytometry analysis for quantifying the number of circulating endothelial progenitor cells (EPCs).
Upper left shows mononuclear cells (MNCs) were gated by forward/sideward scatter (FSC/SSC) in patients with nonalcoholic fatty liver disease
(NAFLD) (A) and without NAFLD (B). The numbers of circulating EPCs were defined as CD34
+, CD34
+KDR
+, and CD34
+KDR
+CD133
+, respectively.
doi:10.1371/journal.pone.0031799.g001
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high-power (6100) microscopic fields.
EPC tube formation assay
An EPC tube formation assay was performed using the In Vitro
Angiogenesis Assay Kit (Chemicon) [23]. ECMatrix gel solution
was thawed overnight at 4uC, mixed with ECMatrix diluent
buffer, and placed in a 96-well plate for 1 h at 37uC to allow the
matrix solution to solidify. Late EPCs were harvested with trypsin/
EDTA, as described above, and 1610
4 EPCs were placed onto a
matrix with EGM-2 MV medium and incubated at 37uC for 16 h.
Tubule formation was inspected with an inverted light microscope
(1006). Six representative fields were used to determine the
average of the total area of complete tubes formed by cells using
the computer software, Image-Pro Plus.
Statistical analysis
Data were expressed as the mean 6 standard deviation (SD) for
numeric variables and as the number (percent) for categorical
variables. Comparisons of continuous variables between groups
were performed by Student’s t test and one-way ANOVA.
Subgroup comparisons of categorical variables were assessed by
Chi-square or Fisher’s exact test. To examine the effects of various
factors on NAFLD, several factors and EPC levels were considered
as confounders for univariate and multivariate logistic regression
analysis separately. Data were analyzed using SPSS software
(version 17, SPSS, Chicago, Illinois, USA). A P value of ,0.05 was
considered to indicate statistical significance.
Results
Clinical and laboratory data
The mean age of the 102 study patients (48 males, 47%) was
70614 years. The patients with NAFLD in the study group and
those without NAFLD in the control group were matched for age
and gender. The baseline characteristics of all study subjects are
presented in Table 1. No significant differences were noted
between the 2 groups, including age, gender, hypertension, type 2
diabetes mellitus, coronary artery disease, peripheral artery
disease, chronic kidney disease, hyperlipidemia, smoking, atrial
fibrillation, or previous history of cerebrovascular disease.
However, NAFLD patients had a higher incidence of metabolic
syndrome, hyperuricemia, and previous myocardial infarction.
There were no significant differences between the 2 groups in
terms of currently used medications, including antiplatelet agents,
angiotensin-converting enzyme inhibitors, angiotensin receptor
blockers, calcium channel blockers, beta blockers, diuretics,
peroxisome proliferator-activated receptor gamma agonists, sta-
tins, nitrates, metformin, and insulin. In addition, patients with
NAFLD had significantly higher waist circumference and BMI
values, as well as increased plasma uric acid and lower HDL-C
levels than those without NAFLD (Table 2).
Table 1. Baseline characteristics of study subjects.
No fatty
liver Fatty liver P value
(n=68) (n=34)
Age (years) 70613 71615 0.191
Male, n (%) 32 (47) 16 (47) 1.000
Hypertension, n (%) 56 (82) 29 (85) 0.925
Type 2 diabetes mellitus, n (%) 26 (38) 16 (47) 0.522
Metabolic syndrome, n (%) 28 (41) 24 (71) 0.010
Coronary artery disease, n (%) 39 (57) 25 (74) 0.169
Peripheral artery disease, n (%) 15 (22) 12 (35) 0.234
Chronic kidney disease, n (%) 27 (40) 17 (50) 0.364
Hyperlipidemia, n (%) 37 (54) 21 (62) 0.621
Current smoker, n (%) 12 (18) 9 (27) 0.311
Previous myocardial infarction, n (%) 14 (21) 15 (44) 0.024
Previous cerebrovascular disease, n (%) 10 (15) 6 (18) 0.923
Atrial fibrillation, n (%) 11 (16) 7 (21) 0.783
Hyperuricemia, n (%) 18 (27) 26 (77) ,0.001
Values are mean 6 standard deviation (SD) or number (%).
doi:10.1371/journal.pone.0031799.t001
Table 2. Metabolic profiles and medications of study
subjects.
No fatty liver
(n=68)
Fatty liver
(n=34) P value
Waist circumference (cm) 84.469.3 89.867.8 0.005
BMI (kg/m
2) 24.664.0 26.765.3 0.029
Cholesterol (mg/dL) 168648 175638 0.406
LDL-C (mg/dL) 98645 106632 0.366
HDL-C (mg/dL) 47613 41612 0.048
Triglyceride (mg/dL) 119662 143690 0.115
Creatinine (mg/dL) 1.862.3 1.962.0 0.972
Total bilirubin (mg/dL) 0.560.2 0.660.4 0.291
ALT (U/L) 23623 35637 0.055
cGT (U/L) 39665 47660 0.723
Uric acid (mg/dL) 5.961.8 7.962.5 ,0.001
Fasting glucose (mg/dL) 135662 136659 0.933
HbA1c (%) 6.960.6 7.160.7 0.370
Medication
Aspirin, n (%) 43 (63) 23 (68) 0.826
Clopidogrel, n (%) 33 (49) 18 (53) 0.834
ACEI, n (%) 9 (13) 3 (9) 0.744
ARB, n (%) 25 (37) 12 (35) 1.000
CCB, n (%) 31 (46) 15 (44) 1.000
Beta blockers, n (%) 27 (40) 15 (44) 0.831
Diuretics, n (%) 23 (34) 13 (38) 0.826
PPAR-c agonists, n (%) 10 (15) 8 (24) 0.409
Statins, n (%) 34 (50) 16 (47) 0.944
Nitrates, n (%) 32 (47) 20 (59) 0.363
Metformin, n (%) 13 (19) 8 (24) 0.612
Insulin , n (%) 7 (10) 5 (15) 0.528
Values are mean 6 standard deviation (SD) or number (%).
HbA1c levels of type 2 diabetes patients.
BMI: body mass index; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-
density lipoprotein cholesterol; ALT: alanine aminotransferase; HbA1c:
Hemoglobin A1c; cGT: gamma-glutamyl transferase; ACEI: angiotensin-
converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium
channel blocker; PPAR-c agonists: peroxisome proliferator-activated receptor
gamma agonists.
doi:10.1371/journal.pone.0031799.t002
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As shown in Table 3, NAFLD patients had significantly
decreased levels of circulating EPCs (CD34
+, CD34
+KDR
+, and
CD34
+KDR
+CD133
+, all P,0.05). For further analysis, subjects
with NAFLD were divided into 3 groups according to the severity
of fatty liver in ultrasonographic analysis: group 1, mild fatty liver
(n=17); group 2, moderate fatty liver (n=10), and group 3, severe
fatty liver (n=7). Circulating EPC numbers were negatively
associated with the severity of fatty liver (No fatty liver vs. mild vs.
moderate vs. severe fatty liver, [mean 6 SD]: CD34
+:
0.093%60.093% vs. 0.033%60.027% vs. 0.032%60.039% vs.
0.015%60.011%, P=0.003; CD34
+KDR
+: 0.024%60.016% vs.
0.006%60.006% vs. 0.006%60.006% vs. 0.002%60.001%,
P,0.001; CD34
+KDR
+CD133
+: 0.021%60.016% vs.
0.006%60.005% vs. 0.004%60.004% vs. 0.002%60.002%,
P,0.001; Figure 2). The characteristics of subjects with mild,
moderate, and severe fatty liver were shown in Table S2 in the
supplemental material.
Characterization of human EPC and functions
Early and late EPCs were isolated from peripheral blood MNCs
of healthy subjects as previously described [23,26]. The peripheral
blood MNCs that initially seeded on fibronectin-coated wells were
round in shape (Figure 3A). After the medium was changed on day
4, attached early EPCs appeared to be elongated with a spindle
shape (Figure 3B). Late EPCs with a cobblestone-like morphology
similar to mature endothelial cells were grown to confluence
(Figure 3C). Early and late EPC characterization were performed
by flow cytometry analysis (CD45) and immunohistochemical
staining, and most of the EPC expressed endothelial and
hematopoietic stem cell markers, VE-cadherin, PECAM-1
(CD31), CD34, KDR, and AC133 (Figure 3), which are
considered critical markers of EPCs, but early and late EPC
markers are different in cell surface makers. (Figure S1) Patients
with NAFLD showed attenuated EPC adhesive function in
comparison to those without NAFLD (control vs. NAFLD,
32.666.3 vs. 15.465.7 cells/HPF, P,0.001; Figure 4A). More-
over, Patients with NAFLD had impaired EPC migration (control
vs. NAFLD, 56.566.9 vs. 27.468.1 cells/HPF, P,0.001; Figure 4B) and tube formation capacity (control vs. NAFLD,
65.0613.5 vs. 45.069.0 cells/HPF, P,0.05; Figure 4C) in
comparison to those without NAFLD.
Patients with NAFLD had significantly higher plasma concen-
trations of hsCRP, a downstream marker of inflammation,
indicating higher systemic inflammation than in the controls
(control vs. NAFLD: 0.9660.96 vs. 1.9361.70 mg/L, P=0.013).
In addition, the plasma levels of ADMA were nonsignificantly
enhanced in patients with NAFLD (control vs. NAFLD:
0.6660.49 vs. 0.7860.42 mmol/L, P=0.269).
Independent correlates of nonalcoholic fatty liver disease
In order to identify the independent predictors of NAFLD,
univariate and multivariate logistic regression analyses were
performed. As shown in Table 4, using univariate analysis,
reduced circulating EPC level (CD34
+KDR
+ [cells/10
5 events]),
metabolic syndrome, uric acid, and hsCRP were found to be
significant predictors of NAFLD. After adjustment for metabolic
syndrome and uric acid levels, circulating EPC level was still an
independent negative predictor of NAFLD (Odds ratio [OR]:
0.78; 95% confidence interval: 0.69–0.89, P,0.001). Although
NAFLD is strongly associated with metabolic syndrome and
diabetes mellitus, EPC level keeps an inverse association with
NAFLD after adjustment for metabolic syndrome and diabetes
mellitus (OR: 0.76; 95% confidence interval: 0.67–0.87,
Figure 2. The association between EPC levels (% and cells/10
5
events) and the severity of non-alcoholic fatty liver disease
(values presented as means ± standard error; FL, fatty liver;
Mild, mild fatty liver; Moderate, moderate fatty liver; Severe,
severe fatty liver).
doi:10.1371/journal.pone.0031799.g002
Table 3. Comparison of the levels of circulating endothelial
progenitor cells, inflammatory markers, and ADMA in fatty
liver patients versus controls.
No fatty liver
(n=68)
Fatty liver
(n=34) P value
EPC levels (%)
CD34
+ 0.09360.093 0.02960.029 0.003
CD34
+KDR
+ 0.02460.016 0.00560.005 ,0.001
CD34
+KDR
+CD133
+ 0.02160.016 0.00560.004 ,0.001
EPC levels (cells/10
5 events)
CD34
+ 86674 30630 0.017
CD34
+KDR
+ 21615 666 ,0.001
CD34
+KDR
+CD133
+ 17614 565 ,0.001
hsCRP (mg/L) 0.9660.96 1.9361.70 0.013
ADMA (mmol/L) 0.6660.49 0.7860.42 0.269
Values are mean 6 standard deviation (SD).
EPC: endothelial progenitor cell; hsCRP: high sensitivity C-reactive protein;
ADMA: asymmetric dimethylarginine.
doi:10.1371/journal.pone.0031799.t003
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smokers and re-analyze whether EPC remained significantly
decreased in patients with NAFLD. Totally, there were 56
controls and 25 fatty liver patients without previous smoking
history. Among them, patients with NAFLD still had significantly
lower EPC numbers compared to controls (P,0.001), and EPC
level (CD34
+KDR
+ [cells/10
5 events]) was still a negative
predictor of fatty liver (OR: 0.79, 0.69–0.90, P=0.001).
Discussion
To the best of our knowledge, this is the first study to show that
patients with NAFLD have decreased circulating EPC numbers
and impaired adhesive function and migration than those without
NAFLD. Furthermore, patients with NAFLD have an enhanced
inflammatory state, and the severity of NAFLD determined on the
basis of ultrasonographic findings is negatively associated with
Figure 3. Morphology and characterization of human endothelial progenitor cells (EPCs) from peripheral blood. Peripheral blood
mononuclear cells (MNCs) were plated on a fibronectin-coated culture dish on the first day (A). Four days after plating, adherent early EPCs with a
spindle shape were shown (B). Three weeks after plating, late EPCs with a cobblestone-like morphology were selected, reseeded, and grown to
confluence (C). Early and late EPC characterization were performed by flow cytometry analysis (CD45) and immunohistochemical staining. Most of the
EPC expressed endothelial and hematopoietic stem cell markers, VE-cadherin, PECAM-1 (CD31), CD34, KDR, and AC133 (Figure 3), which are
considered critical markers of EPCs. Cells were counterstained with 49,6-diamidino-2-phenylindole (DAPI) for the nuclei (blue).
doi:10.1371/journal.pone.0031799.g003
Figure 4. Comparison of the EPC adhesive function (A), migration (B), and tube formation capacities (C) in subjects with or without
fatty liver (values presented as means ± SD; HPF: high-power field; *P,0.05).
doi:10.1371/journal.pone.0031799.g004
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endothelial repair capacity may contribute to atherosclerotic
disease progression and increased risk of cardiovascular events in
NAFLD patients.
NAFLD is a highly prevalent condition characterized by fatty
infiltration of liver cells resembling that of alcohol-induced liver
injury, but it occurs in patients who do not abuse alcohol [1]. It
includes a spectrum of liver damage ranging from simple steatosis
to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and
rarely, progression to cirrhosis. Because the patients with metabolic
syndrome and those with NAFLD have similar clinical character-
istics, an increased risk of cardiovascular disease is expected in
NAFLD patients. Accumulating evidence suggests that cardiovas-
cular mortality is increased in patients with a diagnosis of fatty liver
of nonalcoholic or unspecified causes [27,28]. In a community-
based cohort study of 2,088 male workers, the presence of
ultrasonographic evidence of NAFLD was independently associated
with an increased prevalence of ischemic heart disease [29].
Moreover, in patients consecutively referred for elective coronary
angiography, those with NAFLD have more severe coronary artery
disease, which occurs independent of established conventional
cardiovascular risk factors [30]. Clinical studies further suggest that
NAFLD is a strong risk factor for endothelial dysfunction and
carotid atherosclerosis beyond its association with metabolic
syndrome [31]. However, the pathophysiologic mechanisms
underlying the progression from NAFLD to atherosclerosis and
development of cardiovascular events remain unclear.
The integrity and functional activity of the endothelial
monolayer have been shown to play critical roles in atherogenesis
[32]. Extensive endothelial cell damage caused by cardiovascular
risk factors can result in endothelial cell apoptosis, with subsequent
loss of integrity of the endothelium. The traditional view suggests
that endothelial cell repair is exclusively mediated by the adjacent
endothelial cells. However, a series of basic and clinical studies
prompted by the discovery of bone marrow-derived EPCs have
provided new insights into these processes and indicate that
circulating EPCs play a pivotal role in endothelial cell regener-
ation. Reduced circulating EPC levels independently predict
atherosclerotic disease progression and future cardiovascular
events [17,33], demonstrating an important role of EPCs in
endogenous vascular repair and modulation of the clinical course
of atherosclerosis and cardiovascular disease. In the current study,
we first showed that NAFLD patients had decreased circulating
EPC levels and attenuated EPC adhesive function, which implied
reduced endothelial repair capacity in patients with NAFLD. This
is in agreement with previous studies showing that NAFLD
patients had endothelial dysfunction and advanced atherosclerosis
[19,34]. The association between NAFLD and endothelial
dysfunction, resulting from impaired vascular repair capacity,
may contribute to the higher incidence of cardiovascular events in
NAFLD patients [35].
Recent studies emphasize the roles of insulin resistance,
oxidative stress and subsequent lipid peroxidation, proinflamma-
tory cytokines, adipokines, and mitochondrial dysfunction in the
development and progression of NAFLD. In the current study,
patients with NAFLD, a hepatic presentation of insulin resistance
[36], were shown to have dysfunctional and decreased circulating
EPC levels. The mechanisms to explain the relationship between
NAFLD and reduced EPC level and function remain to be
determined, but are supposed to be related to insulin resistance
and enhanced inflammation in NAFLD patients. Insulin resis-
tance, known to be a cause of endothelial dysfunction, is an
important feature of NAFLD. Previous reports showed that
decreased levels of circulating EPCs were observed in patients
with insulin resistance and metabolic syndrome, and these cases
were characterized by low-grade inflammation and increased
oxidative stress [16,37]. Increased levels of reactive oxygen species
in NAFLD patients may induce subsequent release of pro-
inflammatory cytokines [38,39], which can compromise endothe-
lial function [40]. Enhanced systemic inflammation, and its
association with endothelial dysfunction, has been proven to play
a key role in atherogenesis. Clinical studies indicated that patients
with NAFLD have enhanced inflammation levels in comparison
with the levels in controls [41]. Verma and coworkers showed that
recombinant human CRP directly inhibits EPC differentiation,
survival, and function, at concentrations known to predict adverse
vascular outcomes [42]. Therefore, enhanced inflammation and
insulin resistance observed in patients with NAFLD may suppress
the levels and function of circulating EPCs and attenuated repair
capacity of vasculature.
Reduced EPC levels, which precede the development of
manifested cardiovascular disease, have been shown to play a
major role in the development of atherothrombosis, which might
be due to a decreased capacity to replace damaged or lost
endothelial cells. Reduced EPC levels were an independent
predictor of increased intima-media thickness of the carotid
artery, a strong indicator of subclinical atherosclerotic disease [43].
A recent study showed that NAFLD patients have a greater risk of
carotid atherosclerosis, enlarged mean intima-media thickness,
and higher prevalence of carotid plaques [30]. Our current results
could link the findings of previous studies and provide novel
evidence that NAFLD patients have a higher risk of subclinical
atherosclerosis. The presence and severity of fatty liver should be
carefully monitored as an independent risk factor for cardiovas-
cular diseases. Detection of fatty liver by abdominal sonographic
examination may provide valuable information for cardiovascular
disease risk assessment.
Table 4. Simple correlation and multivariate analysis of
factors associated with nonalcoholic fatty liver disease.
OR (95% CI) P value
Univariate analysis
CD34
+KDR
+ EPCs (cells/10
5 events) 0.74 (0.65–0.85) ,0.001
Age 1.11 (0.81–2.57) 0.805
Male 1.13 (0.49–2.57) 0.778
Hypertension 1.23 (0.39–3.88) 0.728
Diabetes 1.44 (0.62–3.36) 0.391
Hyperlipidemia 1.29 (0.56–3.03) 0.555
Metabolic syndrome 3.90 (1.59–9.55) 0.003
Peripheral artery disease 1.91 (0.76–4.79) 0.169
Coronary artery disease 2.22 (0.90–5.52) 0.085
Chronic kidney disease 1.74 (0.75–4.05) 0.200
Current smoking 1.68 (0.63–4.50) 0.302
Uric acid (mg/dL) 1.61 (1.25–2.08) ,0.001
hsCRP (mg/L) 1.79 (1.07–2.97) 0.026
ADMA (mmol/L) 1.78 (0.61–5.18) 0.293
*Multivariate analysis
CD34
+KDR
+ EPCs (cells/10
5 events) 0.78 (0.69–0.89) ,0.001
OR: odds ratio; CI: confidence interval; EPC: endothelial progenitor cell; hsCRP:
high sensitivity C-reactive protein; ADMA: asymmetric dimethylarginine.
*Multivariate analysis: adjusted for metabolic syndrome and uric acid levels.
doi:10.1371/journal.pone.0031799.t004
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Some limitations should be mentioned in this study. First, the
sample size of this study is rather small. We could only adjust for
two confounders (metabolic syndrome and uric acid level) in the
multivariate analysis because the number of fatty liver patients is
relatively small. Further larger, confirmative studies are needed to
verify the result. Second, because the fatty liver was diagnosed by
abdominal ultrasonography but not by computed tomography or
liver biopsy, we could not negate the possibility that only more
severe fatty liver cases could be detected, since abdominal
ultrasound can detect liver steatosis only when it is greater than
30%. This might bias the result and should be considered a
limitation. Third, we enrolled subjects undergoing diagnostic
coronary angiography in our study, and it might bias the results.
Fourth, we did not check the degree of insulin resistance by
homeostasis model assessment for diabetes patients. Fifth,
although our data show NAFLD per se influence EPC number
and function, NAFLD is indeed strongly associated with metabolic
syndrome and diabetes mellitus. In this study, we could not
exclude the possibility that metabolic syndrome and diabetes may
play a greater role than NAFLD in influencing EPC. Finally, this
was a cross-sectional study, in which we identified an association
between circulating EPC numbers and presence and severity of
NAFLD. Therefore, we could not confirm whether the decrease in
circulating EPCs was the cause or the result of NAFLD. Further
prospective studies should be arranged to clarify the cause-and-
effect relationship and test whether quantification of EPCs levels
could provide additional information over the current risk factors
to predict future cardiovascular events in NAFLD patients.
In conclusion, this study demonstrated for the first time that
NAFLD patients have decreased circulating EPC numbers and
adhesive function than those without NAFLD. These findings
suggest that attenuated endothelial repair capacity may contribute
to atherosclerotic disease progression and enhanced cardiovascular
risk in NAFLD patients. NAFLD should be carefully considered as
an independent risk factor for cardiovascular diseases.
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